Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.
A Sendai virus (SeV) vector is being developed for delivery of an HIV immunogen. SeV is not known to cause disease in humans. Because it is genetically and antigenically related to human parainfluenza virus type 1 (hPIV-1), it is important to determine whether pre-existing hPIV-1 antibodies will aff...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1826287705652199424 |
|---|---|
| author | Hara, H Hara, H Hironaka, T Inoue, M Iida, A Shu, T Hasegawa, M Nagai, Y Falsey, A Kamali, A Anzala, O Sanders, E Karita, E Mwananyanda, L Vasan, S Lombardo, A Parks, C Sayeed, E Krebs, M Cormier, E Ackland, J Price, M Excler, J |
| author_facet | Hara, H Hara, H Hironaka, T Inoue, M Iida, A Shu, T Hasegawa, M Nagai, Y Falsey, A Kamali, A Anzala, O Sanders, E Karita, E Mwananyanda, L Vasan, S Lombardo, A Parks, C Sayeed, E Krebs, M Cormier, E Ackland, J Price, M Excler, J |
| author_sort | Hara, H |
| collection | OXFORD |
| description | A Sendai virus (SeV) vector is being developed for delivery of an HIV immunogen. SeV is not known to cause disease in humans. Because it is genetically and antigenically related to human parainfluenza virus type 1 (hPIV-1), it is important to determine whether pre-existing hPIV-1 antibodies will affect immune responses elicited by a SeV vector-based vaccine. To quantify SeV neutralizing antibodies (NAb) in human serum, a sensitive virus neutralization assay was developed using a SeV vector encoding green fluorescent protein. Samples from 255 HIV-uninfected subjects from Africa, Europe, United States, and Japan, as well as from 12 confirmed hPIV-1-infected patients, were analyzed. SeV NAb titers did not vary significantly after serum was treated with receptor-destroying enzyme, indicating that non-specific hemagglutination inhibitors did not affect the assay sensitivity. A significant correlation was observed between hPIV-1 ELISA and SeV NAb titers. SeV NAb were detected in 92.5% subjects with a median titer of 60.6 and values ranging from 5.9- 11,324. The majority had titers < 1000 with 71.7% < 100 (< 5 considered negative). There was no significant difference in titer or prevalence by gender, age range or geographic origin. However, African males had a lower titer than non-Africans of either gender (p=0.007). Overall, the prevalence of SeV NAb is high and likely due to neutralization by cross-reactive hPIV-1 antibodies. Clinical trials will be needed to assess the influence of pre-existing SeV NAb on HIV-specific immune responses elicited by a SeV vaccine vector expressing HIV. |
| first_indexed | 2024-03-07T02:02:40Z |
| format | Journal article |
| id | oxford-uuid:9de52e6d-55a5-420c-bc19-6e8c598c422d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:02:40Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:9de52e6d-55a5-420c-bc19-6e8c598c422d2022-03-27T00:46:28ZPrevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9de52e6d-55a5-420c-bc19-6e8c598c422dEnglishSymplectic Elements at Oxford2011Hara, HHara, HHironaka, TInoue, MIida, AShu, THasegawa, MNagai, YFalsey, AKamali, AAnzala, OSanders, EKarita, EMwananyanda, LVasan, SLombardo, AParks, CSayeed, EKrebs, MCormier, EAckland, JPrice, MExcler, JA Sendai virus (SeV) vector is being developed for delivery of an HIV immunogen. SeV is not known to cause disease in humans. Because it is genetically and antigenically related to human parainfluenza virus type 1 (hPIV-1), it is important to determine whether pre-existing hPIV-1 antibodies will affect immune responses elicited by a SeV vector-based vaccine. To quantify SeV neutralizing antibodies (NAb) in human serum, a sensitive virus neutralization assay was developed using a SeV vector encoding green fluorescent protein. Samples from 255 HIV-uninfected subjects from Africa, Europe, United States, and Japan, as well as from 12 confirmed hPIV-1-infected patients, were analyzed. SeV NAb titers did not vary significantly after serum was treated with receptor-destroying enzyme, indicating that non-specific hemagglutination inhibitors did not affect the assay sensitivity. A significant correlation was observed between hPIV-1 ELISA and SeV NAb titers. SeV NAb were detected in 92.5% subjects with a median titer of 60.6 and values ranging from 5.9- 11,324. The majority had titers < 1000 with 71.7% < 100 (< 5 considered negative). There was no significant difference in titer or prevalence by gender, age range or geographic origin. However, African males had a lower titer than non-Africans of either gender (p=0.007). Overall, the prevalence of SeV NAb is high and likely due to neutralization by cross-reactive hPIV-1 antibodies. Clinical trials will be needed to assess the influence of pre-existing SeV NAb on HIV-specific immune responses elicited by a SeV vaccine vector expressing HIV. |
| spellingShingle | Hara, H Hara, H Hironaka, T Inoue, M Iida, A Shu, T Hasegawa, M Nagai, Y Falsey, A Kamali, A Anzala, O Sanders, E Karita, E Mwananyanda, L Vasan, S Lombardo, A Parks, C Sayeed, E Krebs, M Cormier, E Ackland, J Price, M Excler, J Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. |
| title | Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. |
| title_full | Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. |
| title_fullStr | Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. |
| title_full_unstemmed | Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. |
| title_short | Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. |
| title_sort | prevalence of specific neutralizing antibodies against sendai virus in populations from different geographic areas implications for aids vaccine development using sendai virus vectors |
| work_keys_str_mv | AT harah prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT harah prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT hironakat prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT inouem prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT iidaa prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT shut prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT hasegawam prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT nagaiy prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT falseya prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT kamalia prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT anzalao prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT sanderse prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT karitae prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT mwananyandal prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT vasans prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT lombardoa prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT parksc prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT sayeede prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT krebsm prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT cormiere prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT acklandj prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT pricem prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors AT exclerj prevalenceofspecificneutralizingantibodiesagainstsendaivirusinpopulationsfromdifferentgeographicareasimplicationsforaidsvaccinedevelopmentusingsendaivirusvectors |